The case against Martin Shkreli and his company is notorious in the annals of pharmaceutical antitrust litigation. But while the outcome puts a spotlight on strategies to block generic competition, it is not expected to impact other brand name drug manufacturers as they have modified their practices in recent years.
The Federal Trade Commission announced that it and seven state co-plaintiffs had filed a stipulated order for a permanent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?